129958@2x.jpg

OPTIMAL phase III trial

PFS was significantly longer in erlotinib-treated Chinese patients with EGFR Mut+ NSCLC compared with that of patients treated with standard chemotherapy. Erlotinib was also better tolerated.1,2

Study design and endpoints1

  • OPTIMAL was a randomised phase III trial that took place across 22 centres in China. 
  • The trial compared erlotinib versus standard chemotherapy as first-line treatment for EGFR Mut+ NSCLC.

 

page_4@2x.png

ECOG PS (Eastern Co-operative Oncology Group performance status)

Key Results

page_5_1@2x.png
Group 393.svg

Efficacy2

Patients receiving erlotinib had longer PFS than patients receiving chemotherapy.

page_5_2@2x.png
Group 394.svg

Safety1

Patients treated with erlotinib experienced fewer treatment related severe AEs, fewer grade 3/4 AEs and fewer dose reductions due to AEs than patients treated with chemotherapy.

Please click here for further safety data